Joel N. Buxbaum
- Molecular Biology top 0.5%
- Physiology top 0.5%
- Cell Biology top 0.5%
- Oncology top 2%
- Nephrology top 0.5%
- Co-authors
- Maria João SaraivaNatàlia ReixachGiampaolo MerliniPer WestermarkMerrill D. BensonJean D. SipeJeffery W. KellyDaniel R. Jacobson
- Topics
- Amyloidosis: Diagnosis, Treatment, Outcomes (85 papers)Alzheimer's disease research and treatments (39 papers)Cellular transport and secretion (26 papers)
- Partner nations
- United StatesItalySweden
In The Last Decade
Joel N. Buxbaum
153 papers receiving 8.0k citations
Hit Papers
Peers
Comparison fields: 5 of 146
- Molecular Biology 6.7k
- Physiology 2.6k
- Cell Biology 1.4k
- Oncology 1.3k
- Nephrology 1.2k
Countries citing papers authored by Joel N. Buxbaum
This map shows the geographic impact of Joel N. Buxbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel N. Buxbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel N. Buxbaum more than expected).
Fields of papers citing papers by Joel N. Buxbaum
This network shows the impact of papers produced by Joel N. Buxbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel N. Buxbaum. The network helps show where Joel N. Buxbaum may publish in the future.
Co-authorship network of co-authors of Joel N. Buxbaum
This figure shows the co-authorship network connecting the top 25 collaborators of Joel N. Buxbaum. A scholar is included among the top collaborators of Joel N. Buxbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel N. Buxbaum. Joel N. Buxbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 16 | |
| 2 | 3 | |
| 3 | 11 | |
| 4 | 110 | |
| 5 | 118 | |
| 6 | 84 | |
| 7 | 26 | |
| 8 | 113 | |
| 9 | 94 | |
| 10 | 6 | |
| 11 | 79 | |
| 12 | 407 | |
| 13 | 7 | |
| 14 | 44 | |
| 15 | T-cell receptor use in human autoimmune diseases | 6 |
| 16 | 7 | |
| 17 | 9 | |
| 18 | Identification of new restriction fragment length polymorphisms associated with familial amyloidotic polyneuropathy | 2 |
| 19 | 21 | |
| 20 | 30 |
About Joel N. Buxbaum
Joel N. Buxbaum is a scholar working on Cell Biology, Physiology and Molecular Biology, having authored 153 papers that have together received 8.3k indexed citations. Recurring topics across this work include Amyloidosis: Diagnosis, Treatment, Outcomes (85 papers), Alzheimer's disease research and treatments (39 papers) and Cellular transport and secretion (26 papers). The work is most often cited by research in Nephrology (1.2k citations), Physiology (2.6k citations) and Molecular Biology (6.7k citations). Joel N. Buxbaum has collaborated with scholars based in United States, Italy and Sweden. Frequent co-authors include Maria João Saraiva, Natàlia Reixach, Giampaolo Merlini, Per Westermark, Merrill D. Benson, Jean D. Sipe, Jeffery W. Kelly, Daniel R. Jacobson, Shu-ichi Ikeda and Gloria Gallo. Their work appears in journals such as Nature, Science and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.